Print Issue: November 01, 2011

Investigational Combo May Prevent Diabetes in Obese Patients

LISBON—The investigational anti-obesity compound known as controlled-release (CR) phentermine/topiramate may prevent progression to type 2 diabetes in obese patients who are prediabetic, researchers announced at the 47th annual meeting of the European Association for the Study of Diabetes.

Next post in Prostate Cancer